Soleno Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8342033094
USD
52.68
4.56 (9.49%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Soleno Therapeutics, Inc. stock-summary
stock-summary
Soleno Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.
Company Coordinates stock-summary
Company Details
1235 Radio Rd Ste 110 , REDWOOD CITY CA : 94065-1217
stock-summary
Tel: 1 650 2138444
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 52 Schemes (26.76%)

Foreign Institutions

Held by 82 Foreign Institutions (13.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Ernest Mario
Independent Chairman of the Board
DR. Anish Bhatnagar
President, Chief Executive Officer, Director
Mr. William Harris
Independent Director
Ms. Gwen Melincoff
Independent Director
Mr. Andrew Sinclair
Independent Director
Dr. Birgitte Volck
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
33 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,842 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.98

stock-summary
Return on Equity

-73.21%

stock-summary
Price to Book

16.00